Emyria in ‘final stages’ of winding down Emerald Clinics by Steve Jones September 3, 2024September 3, 2024 Emyria is winding down its cannabis clinic business to focus on MDMA-assisted therapy as its chief […]
Emyria S3 CBD trial ‘on hold’ as firm stresses need to focus on revenue by Steve Jones February 7, 2024February 7, 2024
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024
Emyria shares take a hit as company raises another A$2.5 million by Steve Jones May 1, 2023April 30, 2024
Emyria strikes commercial deal with Aspen for over-the-counter product by Steve Jones April 4, 2023April 30, 2024
Emyria and LGP shares soar after TGA approves limited access to MDMA and psilocybin by Steve Jones February 6, 2023April 29, 2024
Company news: Althea; Cann Group; Emyria; Neurotech; Bod Science; Elixinol; Creso Pharma; MGC Pharma by Steve Jones and Martin Lane January 31, 2023February 2, 2023
Cannabis risks becoming a ‘borderline supplement’ unless it evolves, warns Emyria chief by Steve Jones August 18, 2022April 29, 2024
We’re coming for you, TGA warns rule-breaking clinics after issuing 32 cease and desist orders by Steve Jones July 15, 2021April 26, 2024
